NVSNovartis PharmaceuticalsRunning, no new patients
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Follicular Lymphoma (FL)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 109 (final count)
- Started
- Oct 2, 2023
- Main results expected
- Jul 25, 2028
- Fully finished
- Feb 20, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS) determined by blinded independent review committee (BIRC)
Measured over: 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05888493 · record last updated 2026-04-17 · checked 2026-11-09 15:47 UTC